Literature DB >> 15314696

Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes.

Peter Achenbach1, Kerstin Koczwara, Annette Knopff, Heike Naserke, Anette-G Ziegler, Ezio Bonifacio.   

Abstract

Children at risk for type 1 diabetes can develop early insulin autoantibodies (IAAs). Many, but not all, of these children subsequently develop multiple islet autoantibodies and diabetes. To determine whether disease progression is reflected by autoantibody maturity, IAA affinity was measured by competitive radiobinding assay in first and subsequent IAA-positive samples from children followed from birth in the BABYDIAB cohort. IAA affinity in first positive samples ranged from less than 10(6) l/mol to more than 10(11) l/mol. High affinity was associated with HLA DRB1*04, young age of IAA appearance, and subsequent progression to multiple islet autoantibodies or type 1 diabetes. IAA affinity in multiple antibody-positive children was on average 100-fold higher than in children who remained single IAA positive or became autoantibody negative. All high-affinity IAAs required conservation of human insulin A chain residues 8-13 and were reactive with proinsulin. In contrast, most lower-affinity IAAs were dependent on COOH-terminal B chain residues and did not bind proinsulin. These data are consistent with the concept that type 1 diabetes is associated with sustained early exposure to (pro)insulin in the context of HLA DR4 and show that high-affinity proinsulin-reactive IAAs identify children with the highest diabetes risk.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15314696      PMCID: PMC503771          DOI: 10.1172/JCI21307

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Proinsulin-specific autoantibodies are relatively infrequent in young offspring with pre-type 1 diabetes.

Authors:  M Hummel; A J Williams; A Norcross; E Standl; E Bonifacio; A G Ziegler; P J Bingley
Journal:  Diabetes Care       Date:  2001-10       Impact factor: 19.112

2.  Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health.

Authors:  Sefina Arif; Timothy I Tree; Thomas P Astill; Jennifer M Tremble; Amanda J Bishop; Colin M Dayan; Bart O Roep; Mark Peakman
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

Review 3.  Type 1 diabetes: new perspectives on disease pathogenesis and treatment.

Authors:  M A Atkinson; G S Eisenbarth
Journal:  Lancet       Date:  2001-07-21       Impact factor: 79.321

4.  Diabetes Antibody Standardization Program: first assay proficiency evaluation.

Authors:  Polly J Bingley; Ezio Bonifacio; Patricia W Mueller
Journal:  Diabetes       Date:  2003-05       Impact factor: 9.461

5.  Proinsulin: a proposed three-dimensional structure.

Authors:  C R Snell; D G Smyth
Journal:  J Biol Chem       Date:  1975-08-25       Impact factor: 5.157

6.  Brief communication: early appearance of islet autoantibodies predicts childhood type 1 diabetes in offspring of diabetic parents.

Authors:  Michael Hummel; Ezio Bonifacio; Sandra Schmid; Markus Walter; Annette Knopff; Anette-G Ziegler
Journal:  Ann Intern Med       Date:  2004-06-01       Impact factor: 25.391

7.  Equilibrium binding studies of insulin antibodies in diabetic subjects.

Authors:  R C Baxter; D K Yue; J R Turtle
Journal:  Clin Chem       Date:  1976-07       Impact factor: 8.327

8.  IDDM2/insulin VNTR modifies risk conferred by IDDM1/HLA for development of Type 1 diabetes and associated autoimmunity.

Authors:  M Walter; E Albert; M Conrad; E Keller; M Hummel; K Ferber; B J Barratt; J A Todd; A-G Ziegler; E Bonifacio
Journal:  Diabetologia       Date:  2003-05-16       Impact factor: 10.122

9.  Pro- and anti-inflammatory cytokine production by autoimmune T cells against preproinsulin in HLA-DRB1*04, DQ8 Type 1 diabetes.

Authors:  I Durinovic-Belló; M Schlosser; M Riedl; N Maisel; S Rosinger; H Kalbacher; M Deeg; M Ziegler; J Elliott; B O Roep; W Karges; B O Boehm
Journal:  Diabetologia       Date:  2004-01-24       Impact factor: 10.122

10.  Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics.

Authors:  Peter Achenbach; Katharina Warncke; Jürgen Reiter; Heike E Naserke; Alistair J K Williams; Polly J Bingley; Ezio Bonifacio; Anette-G Ziegler
Journal:  Diabetes       Date:  2004-02       Impact factor: 9.461

View more
  95 in total

Review 1.  Genes affecting β-cell function in type 1 diabetes.

Authors:  Tina Fløyel; Simranjeet Kaur; Flemming Pociot
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

Review 2.  Insulin as a key autoantigen in the development of type 1 diabetes.

Authors:  Maki Nakayama
Journal:  Diabetes Metab Res Rev       Date:  2011-11       Impact factor: 4.876

3.  Longitudinal epitope analysis of insulin-binding antibodies in type 1 diabetes.

Authors:  T R Hall; J W Thomas; C J Padoa; C Torn; M Landin-Olsson; E Ortqvist; C S Hampe
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

4.  Type 1 diabetes risk assessment: improvement by follow-up measurements in young islet autoantibody-positive relatives.

Authors:  P Achenbach; K Warncke; J Reiter; A J K Williams; A G Ziegler; P J Bingley; E Bonifacio
Journal:  Diabetologia       Date:  2006-09-26       Impact factor: 10.122

Review 5.  Novel diagnostic and therapeutic approaches for autoimmune diabetes--a prime time to treat insulitis as a disease.

Authors:  Juha Grönholm; Michael J Lenardo
Journal:  Clin Immunol       Date:  2014-12-05       Impact factor: 3.969

6.  The A-chain of insulin is a hot-spot for CD4+ T cell epitopes in human type 1 diabetes.

Authors:  S I Mannering; S H Pang; N A Williamson; G Naselli; E C Reynolds; N M O'Brien-Simpson; A W Purcell; L C Harrison
Journal:  Clin Exp Immunol       Date:  2009-03-09       Impact factor: 4.330

7.  GAD autoantibody affinity in schoolchildren from the general population.

Authors:  Christine Bender; Michael Schlosser; Urs Christen; Anette G Ziegler; Peter Achenbach
Journal:  Diabetologia       Date:  2014-06-18       Impact factor: 10.122

Review 8.  Serum biomarkers for diagnosis and prediction of type 1 diabetes.

Authors:  Lian Yi; Adam C Swensen; Wei-Jun Qian
Journal:  Transl Res       Date:  2018-08-01       Impact factor: 7.012

9.  Retro-inverso D-peptides as a novel targeted immunotherapy for Type 1 diabetes.

Authors:  Angela Lombardi; Erlinda Concepcion; Hanxi Hou; Hanane Arib; Mihaly Mezei; Roman Osman; Yaron Tomer
Journal:  J Autoimmun       Date:  2020-09-17       Impact factor: 7.094

10.  Characteristics of rapid vs slow progression to type 1 diabetes in multiple islet autoantibody-positive children.

Authors:  P Achenbach; M Hummel; L Thümer; H Boerschmann; D Höfelmann; A G Ziegler
Journal:  Diabetologia       Date:  2013-03-29       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.